NCT06999200

Brief Summary

In the management of pain after Caesarean section (C/S), opioid or nonsteroidal anti-inflammatory parenteral drugs are applied. These drugs are insufficient in some cases and may cause pain attacks during the day. Higher doses and repeated drug applications or combined drug administration may cause drug side effects and interactions. Alternative applications to provide analgesia include subcutaneous and intracutaneous local anesthetic application to the wound site. Although the effectiveness of these applications has been tested in individuals with different clinical characteristics and has been shown to be largely more successful, they have not been sufficiently introduced into routine practice. There is a need to review the pain methods suggested in the literature and develop new solutions that can be applied more optimally, improve the patient's pain management in the postoperative period, and increase their quality of life and satisfaction. It aims to evaluate the success of subcutaneous and intracutaneous local anesthesia applications compared to traditional applications, and to find the most optimal management.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
156

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

May 31, 2025

Completed
10 days until next milestone

Study Start

First participant enrolled

June 10, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2025

Completed
Last Updated

May 31, 2025

Status Verified

May 1, 2025

Enrollment Period

3 months

First QC Date

May 7, 2025

Last Update Submit

May 22, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual analogue scale

    1=no pain, 10=worst pain

    48 hours

Study Arms (3)

Subcutaneous local anesthesia group

who received subcutaneous local anesthesia at the end of C/S surgery

Drug: neural therapy

Intracutaneous local anesthesia group

who received intracutaneous local anesthesia at the end of C/S surgery

Drug: neural therapy

Parenteral analgesia group

who received parenteral analgesia after C/S surgery

Drug: neural therapy

Interventions

This prospective study will be conducted with mothers who underwent general anesthesia for labor or elective cesarean delivery and local anesthesia for postoperative pain management during a one-year period following ethical approval.

Intracutaneous local anesthesia groupParenteral analgesia groupSubcutaneous local anesthesia group

Eligibility Criteria

Age19 Years - 45 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women aged 19-45 who underwent a caesarean section under general anesthesia

You may qualify if:

  • Healthy pregnancy,
  • Term (\>37 weeks) and preterm (28-34 weeks) pregnancy,
  • Cases that received general anesthesia for cesarean section,
  • Cases with and without labor,
  • Cases with and without obesity,
  • Cases that had their first or second cesarean section

You may not qualify if:

  • Pregnant women under 19 years of age,
  • Those with a history of allergic reactions to analgesics to be used,
  • Stillbirth,
  • Surgical complications during C/S and placement of an abdominal drain,
  • No head or breech presentation during C/S,
  • Occiput posterior presentation during C/S,
  • Anhydramnios and polyhydramnios,
  • Allergic reactions to the drugs used in the study, alcohol dependence, drug and substance dependence, chronic pain syndrome, neuropathic pain disorder history,
  • History of clinically significant cardiovascular, pulmonary, hepatic, renal, neurological, psychiatric, metabolic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Reed SE, Tan HS, Fuller ME, Krishnamoorthy V, Ohnuma T, Raghunathan K, Habib AS. Analgesia After Cesarean Delivery in the United States 2008-2018: A Retrospective Cohort Study. Anesth Analg. 2021 Dec 1;133(6):1550-1558. doi: 10.1213/ANE.0000000000005587.

  • Roofthooft E, Joshi GP, Rawal N, Van de Velde M; PROSPECT Working Group* of the European Society of Regional Anaesthesia and Pain Therapy and supported by the Obstetric Anaesthetists' Association. PROSPECT guideline for elective caesarean section: updated systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia. 2021 May;76(5):665-680. doi: 10.1111/anae.15339. Epub 2020 Dec 28.

MeSH Terms

Interventions

Anesthesia, Local

Intervention Hierarchy (Ancestors)

Anesthesia, ConductionAnesthesiaAnesthesia and Analgesia

Central Study Contacts

emine yılmaz güler

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 7, 2025

First Posted

May 31, 2025

Study Start

June 10, 2025

Primary Completion

September 10, 2025

Study Completion

October 10, 2025

Last Updated

May 31, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share